As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper knockoff versions of popular weight loss drugs, Novo Nordisk will not have to | A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA.

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events. Central to this rise was the encouraging long-term efficacy data for its drug EBGLYSS in treating atopic dermatitis,

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out. | A Texas court has rejected a request by compounders to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate an evolving mindset toward treating obesity as a chronic disease.

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down ... Cardiometabolic Health at Eli Lilly and Company, told Health.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,